Figure 3From: Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexateMethotrexate decreases the synovial RANKL/OPG ratio in early-untreated rheumatoid arthritis. Synovial receptor activator of the NF-κB ligand (RANKL)/osteoprotegerin (OPG) ratio as evaluated by semi-quantitative double-blind microscopic analysis. *P <0.05.Back to article page